Analytical Data
-
基因名
HLA-A*02:01&B2M&KRAS G12V(VVVGAVGVGK) Monomer
- Application
-
别名
HLA-A*0201 & B2M & KRASG12V (VVVGAVGVGK)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&VVVGAVGVGK
-
分子量
40-43 kDa and 10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*02:01 in conjunction with beta-2-microglobulin (β2M) and the KRAS G12V mutation has garnered significant attention in the field of immunology and cancer research. HLA-A*02:01 is a prevalent human leukocyte antigen (HLA) allele that plays a crucial role in the immune system by presenting peptides to CD8+ T cells, thereby facilitating the recognition of tumor-specific antigens. KRAS mutations, such as G12V, are common in various cancers, including pancreatic, colorectal, and lung cancers, leading to aberrant cell signaling and proliferation. The KRAS G12V peptide (VVVGAVGVGK) becomes a target for T cell-mediated immunity, making it an ideal candidate for therapeutic development. The reconstitution of the HLA-A*02:01-β2M complex with the KRAS G12V peptide into a monomeric form allows for more precise studies of T cell responses and the design of peptide-based immunotherapies. Understanding the interaction between the HLA-A*02:01/β2M complex and the KRAS G12V peptide can provide insights into the efficacy of vaccine strategies that aim to provoke an immune response against KRAS-driven tumors. This research could lead to novel therapeutic approaches, enhancing the effectiveness of current cancer treatments and improving patient outcomes.
